Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852058 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
NCT01852058 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 95 participants.
The verdict
NCT01852058, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully completed Study 191622-120 (NCT01852045).
Interventions
- BIOLOGICAL OnabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-01-11 |
| Est. Completion | 2019-10-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852058
The ClinicalTrials.gov registry entry for NCT01852058 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OnabotulinumtoxinA is the first listed.
NCT01852058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852058 about?
NCT01852058 is a clinical study titled "A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity". This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully completed Study 191622-120 (NCT01852045).
What is the current status of trial NCT01852058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2014-01-11. Estimated completion is 2019-10-03.
What interventions are being tested in trial NCT01852058?
The interventions under investigation include: OnabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT01852058?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.